JP2004529161A5 - - Google Patents

Download PDF

Info

Publication number
JP2004529161A5
JP2004529161A5 JP2002586869A JP2002586869A JP2004529161A5 JP 2004529161 A5 JP2004529161 A5 JP 2004529161A5 JP 2002586869 A JP2002586869 A JP 2002586869A JP 2002586869 A JP2002586869 A JP 2002586869A JP 2004529161 A5 JP2004529161 A5 JP 2004529161A5
Authority
JP
Japan
Prior art keywords
alkyl
aryl
hydrogen
group
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002586869A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004529161A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/013856 external-priority patent/WO2002089729A2/en
Publication of JP2004529161A publication Critical patent/JP2004529161A/ja
Publication of JP2004529161A5 publication Critical patent/JP2004529161A5/ja
Pending legal-status Critical Current

Links

JP2002586869A 2001-05-04 2002-05-03 縮合複素環式化合物 Pending JP2004529161A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28866501P 2001-05-04 2001-05-04
PCT/US2002/013856 WO2002089729A2 (en) 2001-05-04 2002-05-03 Fused heterocyclic compounds

Publications (2)

Publication Number Publication Date
JP2004529161A JP2004529161A (ja) 2004-09-24
JP2004529161A5 true JP2004529161A5 (https=) 2005-12-22

Family

ID=23108101

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002586869A Pending JP2004529161A (ja) 2001-05-04 2002-05-03 縮合複素環式化合物

Country Status (9)

Country Link
US (1) US6858619B2 (https=)
EP (1) EP1392298B1 (https=)
JP (1) JP2004529161A (https=)
AT (1) ATE422887T1 (https=)
AU (1) AU2002305323A1 (https=)
CA (1) CA2446351A1 (https=)
DE (1) DE60231202D1 (https=)
ES (1) ES2319619T3 (https=)
WO (1) WO2002089729A2 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE422887T1 (de) 2001-05-04 2009-03-15 Amgen Inc Kondensierte heterozyklische verbindungen
US6809104B2 (en) 2001-05-04 2004-10-26 Tularik Inc. Fused heterocyclic compounds
US20070135425A1 (en) * 2001-05-04 2007-06-14 Amgen Inc. Fused heterocyclic compounds
CA2468015A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 2-aminoquinoline compounds
AU2002352868A1 (en) * 2001-11-27 2003-06-10 Merck & Co., Inc. 4-aminoquinoline compounds
CA2473236A1 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1h-benzoimidazole analogues
EP1465888A2 (en) 2002-01-10 2004-10-13 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
US7253179B2 (en) 2002-11-06 2007-08-07 Amgen Inc. Fused heterocyclic compounds
US7727998B2 (en) * 2003-02-10 2010-06-01 Banyu Pharmaceutical Co., Ltd. Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
US7241787B2 (en) 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
DE102004039789A1 (de) 2004-08-16 2006-03-02 Sanofi-Aventis Deutschland Gmbh Arylsubstituierte polycyclische Amine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN101273026A (zh) 2005-09-30 2008-09-24 霍夫曼-拉罗奇有限公司 作为mch受体拮抗剂的茚满衍生物
KR20080094699A (ko) 2006-02-15 2008-10-23 사노피-아벤티스 신규 아미노알콜-치환된 아릴디하이드로이소퀴놀리논, 이의제조 방법 및 이의 약물로서의 용도
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
UY32442A (es) 2009-02-13 2010-09-30 Sanofi Aventis Nuevos indanos sustituidos, procesos para su preparacion y uso de los mismos como un medicamento
TW201040153A (en) 2009-02-13 2010-11-16 Sanofi Aventis Novel substituted tetrahydronaphthalenes, process for preparation thereof and use thereof as medicaments
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
US8575186B2 (en) 2009-10-05 2013-11-05 Albany Molecular Research, Inc. Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof
AU2012207335A1 (en) 2011-01-19 2013-07-25 Albany Molecular Research, Inc. Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-HT6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
JP2015509969A (ja) * 2012-03-16 2015-04-02 グルソックス・バイオテック・アーベー Ｎｏｘ４阻害活性を示すチオフェン−ベースの化合物および療法におけるその使用
JP6274384B2 (ja) * 2012-04-27 2018-02-07 Nok株式会社 メタルガスケット及びその製造方法
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2906654B2 (ja) 1989-11-28 1999-06-21 東レ株式会社 免疫抑制剤及びその製造方法
EP0596897B1 (en) * 1991-07-05 2002-03-13 Smithkline Becham S.P.A. Hydroisoquinoline derivatives
CN1043766C (zh) 1992-09-29 1999-06-23 东丽株式会社 吲哚衍生物及其制法和它们在制备药物中的应用
US5464841A (en) 1993-11-08 1995-11-07 Univ Minnesota Use of delta opioid receptor antagonists to treat immunoregulatory disorders
US5578725A (en) 1995-01-30 1996-11-26 Regents Of The University Of Minnesota Delta opioid receptor antagonists
ES2217533T3 (es) 1997-01-16 2004-11-01 Toray Industries, Inc. Derivados de indolomorfinano y medicamentos/preventivos para transtornos cerebrales.
EP1120872B1 (en) 1998-10-07 2006-12-20 Sharp Kabushiki Kaisha Semiconductor laser
GB9822158D0 (en) 1998-10-09 1998-12-02 Nycomed Imaging As Compositions
EP1153932A1 (en) 1999-02-19 2001-11-14 Takeda Chemical Industries, Ltd. Novel g protein-coupled receptor protein and dna thereof
EP1196572A1 (en) 1999-07-27 2002-04-17 Smithkline Beecham Plc Axor21, a g-protein coupled receptor
JP2001226269A (ja) 2000-02-18 2001-08-21 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
EP1298439B1 (en) 2000-07-05 2010-11-24 Takeda Pharmaceutical Company Limited Method for screening mch receptor antagonist/agonist
EP1299362A4 (en) 2000-07-05 2004-11-03 Synaptic Pharma Corp SELECTIVE RECEPTOR ANTAGONISTS OF MELANINE CONCENTRATING HORMON-1 (MCH1) AND THEIR USE
JP2004502423A (ja) 2000-07-05 2004-01-29 シナプティック・ファーマスーティカル・コーポレーション ヒトメラニン濃縮ホルモン受容体（ｍｃｈ１）をコードするｄｎａ及びその使用
JP2004516239A (ja) 2000-07-06 2004-06-03 ニューロジェン コーポレイション メラニン凝集ホルモン受容体リガンド
CZ20031012A3 (en) 2000-10-20 2004-04-14 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists
US20030022891A1 (en) 2000-12-01 2003-01-30 Anandan Palani MCH antagonists and their use in the treatment of obesity
HK1054390B (en) 2000-12-22 2006-01-06 Schering Corporation Piperidine mch antagonists and their use in the treatment of obesity
US6900329B2 (en) 2001-03-21 2005-05-31 Schering Corporation MCH antagonists and their use in the treatment of obesity
US7034056B2 (en) 2001-03-21 2006-04-25 Pharmacopeia Drug Discovery, Inc. Aryl and biaryl compounds having MCH modulatory activity
PE20021081A1 (es) 2001-04-12 2002-12-18 Pharmacopeia Drug Discovery Aril y biaril piperidinas con actividad moduladora mch
ATE422887T1 (de) 2001-05-04 2009-03-15 Amgen Inc Kondensierte heterozyklische verbindungen
IL158941A0 (en) 2001-05-22 2004-05-12 Neurogen Corp Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues

Similar Documents

Publication Publication Date Title
JP2004529161A5 (https=)
JP4345230B2 (ja) カルボン酸誘導体およびその誘導体を有効成分として含有する薬剤
JP5697163B2 (ja) 置換された３−ヒドロキシ−４−ピリドン誘導体
CN1534023A (zh) 作为多巴胺－d3配位体的杂环化合物
CN1124269C (zh) 取代的嘧啶化合物和其用途
JP5985611B2 (ja) 炎症および免疫関連用途のための化合物
JP2007504284A5 (https=)
TW201625536A (zh) 抑制組蛋白去甲基酶之化合物及方法
JP2002520309A5 (https=)
TW201124379A (en) Aryl substituted sulfonamide compounds and their use as anticancer agents
JP2005508967A5 (https=)
JP2012236838A5 (https=)
JP2009524611A5 (ja) Ｓ１ｐ１受容体アゴニスト、免疫抑制剤および抗炎症剤としての３，５ージ（アリールまたはヘテロアリール）イソキサゾールおよび１，２，４−オキサジアゾール
JP2016505063A (ja) ソルチリン阻害剤としてのｎ置換された５置換フタルアミド酸
CN1400969A (zh) 稠合的咪唑鎓衍生物
JP2004517813A5 (https=)
CN105143188B (zh) 新型磺酰胺trpa1受体拮抗剂
CN103717593A (zh) 调节激酶的组合物和方法
JP2005511545A5 (https=)
JP2005536519A5 (https=)
JP2022539126A (ja) ベンゾジアゼピン系化合物及びその製造方法並びに医薬における作用
JPH10287651A5 (https=)
JP2009502921A5 (https=)
RU2004117595A (ru) Производные пиридина в качестве лигандов рецептора nmda
JP2004525178A5 (https=)